A Functional Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension

Background— Excessive proliferation of pulmonary artery smooth muscle cells (PASMCs) plays an important role in the development of idiopathic pulmonary arterial hypertension (IPAH), whereas a rise in cytosolic Ca2+ concentration triggers PASMC contraction and stimulates PASMC proliferation. Recently, we demonstrated that upregulation of the TRPC6 channel contributes to proliferation of PASMCs isolated from IPAH patients. This study sought to identify single-nucleotide polymorphisms (SNPs) in the TRPC6 gene promoter that are associated with IPAH and have functional significance in regulating TRPC6 activity in PASMCs. Methods and Results— Genomic DNA was isolated from blood samples of 237 normal subjects and 268 IPAH patients. Three biallelic SNPs, −361 (A/T), −254(C/G), and −218 (C/T), were identified in the 2000-bp sequence upstream of the transcriptional start site of TRPC6. Although the allele frequencies of the −361 and −218 SNPs were not different between the groups, the allele frequency of the −254(C→G) SNP in IPAH patients (12%) was significantly higher than in normal subjects (6%; P<0.01). Genotype data showed that the percentage of −254G/G homozygotes in IPAH patients was 2.85 times that of normal subjects. Moreover, the −254(C→G) SNP creates a binding sequence for nuclear factor-&kgr;B. Functional analyses revealed that the −254(C→G) SNP enhanced nuclear factor-&kgr;B–mediated promoter activity and stimulated TRPC6 expression in PASMCs. Inhibition of nuclear factor-&kgr;B activity attenuated TRPC6 expression and decreased agonist-activated Ca2+ influx in PASMCs of IPAH patients harboring the −254G allele. Conclusions— These results suggest that the −254(C→G) SNP may predispose individuals to an increased risk of IPAH by linking abnormal TRPC6 transcription to nuclear factor-&kgr;B, an inflammatory transcription factor.

[1]  J. A. Peters,et al.  Transient receptor potential cation channels in disease. , 2007, Physiological reviews.

[2]  Benjamin R. Rost,et al.  Cation channels of the transient receptor potential superfamily: their role in physiological and pathophysiological processes of smooth muscle cells. , 2006, Pharmacology & therapeutics.

[3]  John McAnally,et al.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. , 2006, The Journal of clinical investigation.

[4]  M. Nishida,et al.  Transient Receptor Potential Channels in Cardiovascular Function and Disease , 2006, Circulation research.

[5]  Lan Liu,et al.  Induced TRPC1 expression sensitizes intestinal epithelial cells to apoptosis by inhibiting NF-kappaB activation through Ca2+ influx. , 2006, The Biochemical journal.

[6]  G. Semenza,et al.  Hypoxia Inducible Factor 1 Mediates Hypoxia-Induced TRPC Expression and Elevated Intracellular Ca2+ in Pulmonary Arterial Smooth Muscle Cells , 2006, Circulation research.

[7]  N. Rudarakanchana,et al.  Serotonin Increases Susceptibility to Pulmonary Hypertension in BMPR2-Deficient Mice , 2006, Circulation research.

[8]  G. Semenza,et al.  Hypoxia Inducible Factor 1 Mediates Hypoxia-Induced TRPC Expression and Elevated Intracellular Ca 2 in Pulmonary Arterial Smooth Muscle Cells , 2006 .

[9]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[10]  T. Gudermann,et al.  Increased Vascular Smooth Muscle Contractility in TRPC6−/− Mice , 2005, Molecular and Cellular Biology.

[11]  J. Loscalzo,et al.  Increased Susceptibility to Pulmonary Hypertension in Heterozygous BMPR2-Mutant Mice , 2005, Circulation.

[12]  I. Fantozzi,et al.  Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Tse,et al.  Chronic Hypoxia–Induced Upregulation of Store-Operated and Receptor-Operated Ca2 Channels in Pulmonary Arterial Smooth Muscle Cells: A Novel Mechanism of Hypoxic Pulmonary Hypertension , 2004, Circulation research.

[14]  J. Knowles,et al.  Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. , 2004, Circulation.

[15]  K. Brown,et al.  Expression of human herpesvirus 8 in primary pulmonary hypertension. , 2003, The New England journal of medicine.

[16]  Ying Yu,et al.  PDGF stimulates pulmonary vascular smooth muscle cell proliferation by upregulating TRPC6 expression. , 2003, American journal of physiology. Cell physiology.

[17]  N. Petrosillo,et al.  Pathogenesis of HIV‐Related Pulmonary Hypertension , 2001, Annals of the New York Academy of Sciences.

[18]  J. Morrow,et al.  Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. , 2001, Chest.

[19]  M. Humbert,et al.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.

[20]  John Arul Phillips,et al.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. , 2001, The New England journal of medicine.

[21]  M. Humbert,et al.  Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[22]  D. Clapham,et al.  The trp ion channel family , 2001, Nature Reviews Neuroscience.

[23]  R. Bush,et al.  Predicting adaptive evolution , 2001, Nature Reviews Genetics.

[24]  D. Saffen,et al.  Muscarinic Acetylcholine Receptor Regulation of TRP6 Ca2+ Channel Isoforms , 2001, The Journal of Biological Chemistry.

[25]  C. L. Bailey,et al.  Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. , 2001, American journal of physiology. Heart and circulatory physiology.

[26]  T. Wood,et al.  Identification and Characterization of Nuclear Factor κB Binding Sites in the Murine bcl‐χ Promoter , 2000, Journal of neurochemistry.

[27]  M. Berridge,et al.  The versatility and universality of calcium signalling , 2000, Nature Reviews Molecular Cell Biology.

[28]  R. Trembath,et al.  Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.

[29]  J. Orens,et al.  Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.

[30]  S. Hodge,et al.  Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. , 1997, Circulation.

[31]  R. Mecham,et al.  Cellular and molecular mechanisms of pulmonary vascular remodeling. , 1997, Annual review of physiology.

[32]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[33]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[34]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[35]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[36]  D. Buff.  Primary pulmonary hypertension. , 1987, Annals of internal medicine.

[37]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.